Wennerberg J, Biörklund A, Tropé C
Department of Otorhinolaryngology, University Hospital, Lund, Sweden.
Arch Otolaryngol Head Neck Surg. 1988 Feb;114(2):162-7. doi: 10.1001/archotol.1988.01860140060022.
In combined modality treatment, cisplatin and fluorouracil are considered to act synergistically. The assumption is based on results in murine leukemias and has not hitherto been tested on human squamous cell carcinoma. In the present study, cisplatin and fluorouracil, used singly and in combination, were tested on two human squamous cell carcinomas of the head and neck, xenografted to nude mice. Cisplatin (7.5 mg/kg) was given as a single-dose intraperitoneal injection and fluorouracil as repeated intraperitoneal injections every eight hours for four days to a total dose of 200 mg/kg. The toxicity of the cisplatin and fluorouracil combination was lower (27%) than that of fluorouracil alone (50%). Both drugs gave a dose-dependent inhibition of tumor volume growth. Using gained growth delay as endpoint, cisplatin and fluorouracil therapy exhibited a synergistic effect on both tumor lines.
在联合治疗中，顺铂和氟尿嘧啶被认为具有协同作用。这一假设基于对小鼠白血病的研究结果，迄今为止尚未在人类鳞状细胞癌上进行过测试。在本研究中，将顺铂和氟尿嘧啶单独及联合使用，对移植到裸鼠体内的两个人类头颈部鳞状细胞癌进行了测试。顺铂（7.5毫克/千克）以单次腹腔注射给药，氟尿嘧啶则每8小时重复腹腔注射一次，共注射4天，总剂量为200毫克/千克。顺铂和氟尿嘧啶联合使用的毒性（27%）低于单独使用氟尿嘧啶的毒性（50%）。两种药物均对肿瘤体积生长产生剂量依赖性抑制。以获得的生长延迟为终点，顺铂和氟尿嘧啶治疗对两种肿瘤细胞系均表现出协同作用。
